BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vebreltinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vebreltinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06343064-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: V
 ebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplific
 ation or MET Overexpression Following EGFR-TKI\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vebreltinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06343064
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Vebreltinib\, phase 2.\nStudy: Precision Medicine Trial Based o
 n Molecular Matching Therapy for Patients With Standard Treatment Exhausti
 on\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743505-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT04743505)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of Combining APL-101 With Frontline Osimertinib in Pati
 ents With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 31 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04743505
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087223-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT07087223)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With 
 c-Met Amplification After EGFR-TKI Failure\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebreltin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7087223
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549061-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07549061)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing 
 NSCLC\nEstimated primary completion: 1 September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07549061
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153770-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07153770)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Boz
 itinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC 
 MET-Altered Non-Small Cell Lung Cancer\nEstimated primary completion: 20 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebrel
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07153770
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156604-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07156604)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebreltinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 56604
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655622-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT07655622)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: V
 ebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-s
 mall Cell Lung Cancer and High PD-L1 Expression\nEstimated primary complet
 ion: 3 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vebreltinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07655622
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patien
 ts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGFR
 -TKI Failure\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930794-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06930794)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Vebreltinib and Platinum-Containing Double Agents in Subjects With
  MET-Positive\nEstimated primary completion: February 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06930794
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644313-2213@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT06644313)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cel
 l Lung Cancer (NSCLC)\nEstimated primary completion: 1 November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06644313
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
